文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌消化内镜

幽门螺杆菌阳性个体中根除治疗预防胃癌:随机对照试验与观察性研究的系统评价与Meta分析

Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
PubMed 文献 · Gastroenterology · 2025-01-15

该系统评价与Meta分析检索至2024年10月4日的文献,纳入11项随机对照试验和13项观察性研究,评估根除治疗对幽门螺杆菌阳性成人胃癌发生率与死亡率的影响。随机对照试验中,根除治疗降低健康幽门螺杆菌阳性个体的胃癌风险(RR 0.64,95%CI 0.48-0.84)及接受内镜下黏膜切除的胃癌患者风险(RR 0.52,95%CI 0.38-0.71);观察性研究结果一致。

要点

  • 随机对照试验显示根除治疗降低健康幽门螺杆菌阳性个体胃癌风险(RR 0.64,95%CI 0.48-0.84)。
  • 随机对照试验显示根除治疗降低胃癌患者内镜下黏膜切除后胃癌风险(RR 0.52,95%CI 0.38-0.71)。
  • 观察性研究与随机对照试验结果一致,支持根除治疗预防胃癌。

核心结论

  • 该Meta分析提供进一步证据表明根除治疗可预防幽门螺杆菌阳性个体的胃癌,不同设计研究结果一致。

研究设计与样本

  • 系统评价与Meta分析,检索截至2024年10月4日的文献,纳入11项随机对照试验和13项观察性研究。
  • 纳入标准为幽门螺杆菌阳性无胃癌成人或接受内镜下黏膜切除的胃癌患者,随访至少2年。
  • 随机对照试验对照组接受安慰剂或无根除治疗,观察性研究对照组无根除治疗。

主要发现

  • 随机对照试验中,健康幽门螺杆菌阳性个体根除治疗组胃癌相对风险低于对照组(8项随机对照试验,RR 0.64,95%CI 0.48-0.84)。
  • 随机对照试验中,接受内镜下黏膜切除的胃癌患者根除治疗组胃癌相对风险低于对照组(3项随机对照试验,RR 0.52,95%CI 0.38-0.71)。
  • 随机对照试验中,健康幽门螺杆菌阳性个体根除治疗组胃癌死亡相对风险低于对照组(5项随机对照试验,RR 0.78,95%CI 0.62-0.98)。
  • 观察性研究中,基线无胃癌的幽门螺杆菌阳性受试者根除治疗组未来胃癌相对风险低于对照组(11项研究,RR 0.56,95%CI 0.43-0.73)。
  • 观察性研究中,接受内镜下黏膜切除的胃癌患者根除治疗组未来胃癌相对风险低于对照组(2项研究,RR 0.19,95%CI 0.06-0.61)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Screening for, and treating, Helicobacter pylori in the general population or patients with early gastric neoplasia could reduce incidence of, and mortality from, gastric cancer. We updated a meta-analysis of randomized controlled trials (RCTs) examining this issue. METHODS: We searched the literature through October 4, 2024, identifying studies examining effect of eradication therapy on incidence of gastric cancer in H pylori-positive adults without gastric neoplasia at baseline or H pylori-positive patients with gastric neoplasia undergoing endoscopic mucosal resection (EMR) in either RCTs or observational studies. The control arm received placebo or no eradication therapy in RCTs and no eradication therapy in observational studies. Follow-up was ≥2 years. We estimated relative risks (RR) of gastric cancer incidence and mortality. RESULTS: Eleven RCTs and 13 observational studies were eligible. For RCTs, RR of gastric cancer was lower with eradication therapy in healthy H pylori-positive individuals (8 RCTs, 0.64; 95% confidence interval [CI], 0.48-0.84) and H pylori-positive patients with gastric neoplasia undergoing EMR (3 RCTs, 0.52; 95% CI, 0.38-0.71). RR of death from gastric cancer was lower with eradication therapy in healthy H pylori-positive individuals (5 RCTs, 0.78; 95% CI, 0.62-0.98). In observational studies, RR of future gastric cancer was lower with eradication therapy in H pylori-positive subjects without gastric neoplasia at baseline (11 studies, 0.56; 95% CI, 0.43-0.73) and H pylori-positive patients with gastric neoplasia undergoing EMR (2 studies, 0.19; 95% CI, 0.06-0.61). CONCLUSIONS: This meta-analysis provides further evidence that administering eradication therapy prevents gastric cancer in H pylori-positive individuals, with consistency in results among studies of different design.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ford AC, Yuan Y, Park JY, et al. Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Gastroenterology. 2025. PMID: 39824392. doi:10.1053/j.gastro.2024.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。